Werewolf Therapeutics Stock (NASDAQ: HOWL)

Werewolf Therapeutics

WEREWOLF THERAPEUTICS INC

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

News

Penny Stocks

Short Ideas

Small Cap

Markets

Trading Ideas

AURA

CVRX

DRMA

HOWL

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Top 5 Health Care Stocks That May Fall Off A Cliff This Month

Intraday Update

Movers

ALLO

AMCX

ATGL

AVDX

BHIL

BILL

BOOM

BSFC

CYTO

DMTK

DOCN

DRIO

EDIT

EIGR

ENGN

ENLV

EXPE

FIGS

FNKO

FOXF

FTNT

HIPO

INSG

LILM

MCRB

MERC

NEXI

NLOP

NVOS

OTLY

PBLA

PCTY

PRLB

PUYI

QRTEA

RDFN

RXRX

SYRA

TNON

TRUP

UDMY

VIVK

VSME

Gainers


	Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.


Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Biotech

Health Care

General

Werewolf Therapeutics Inc (NASDAQ: HOWL) released preliminary results from initial monotherapy dose-escalation cohorts of an ongoing Phase 1/1b trial of WTX-124 in patients with advanced or 

Werewolf Therapeutics&#39; Cancer Drug Shows Promise in Early Study for Solid Tumors, Stock Soars

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics Inc

Earnings

Press Releases

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Management

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

Werewolf Therapeutics to Participate in the BIO International Convention

Adicet Bio

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

CervoMed

Fortress Biotech

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

InflaRx

Opus Genetics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Kronos Bio

MAIA Biotechnology

MDxHealth

Metagenomi

MediciNova

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

Oncolytics Biotech

PMV Pharma

Renovaro

Repare Therapeutics

Serina Therapeutics

Senti Biosciences

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Wedbush

HC Wainwright & Co.

JMP Securities

EF Hutton

B of A Securities

Comments

Werewolf Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell